Source link : https://www.newshealth.biz/health-news/palbociclib-combo-tops-chemo-in-high-risk-breast-cancer/
The phase III PADMA trial demonstrated that first-line treatment with palbociclib plus endocrine therapy (ET) significantly improves outcomes compared with standard mono chemotherapy in patients with high-risk hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2−) metastatic breast cancer. The findings, presented at San Antonio Breast Cancer Symposium (SABCS) 2024 provide evidence […]
Author : News Health
Publish date : 2024-12-16 09:38:36
Copyright for syndicated content belongs to the linked Source.